Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 7/20 | 0.59 |
| ▸ | KDM2B | Q8NHM5 | 12/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3461210 | 0.87 | BCHE (0.51) | BCHEKDM2BSMN1; SMN2 | |
| SCHEMBL28192435 | 0.86 | BCHE (0.78) | BCHEKDM2BSMN1; SMN2 | |
| SCHEMBL17919850 | 0.85 | BCHE (0.57) | BCHEKDM2B | |
| SCHEMBL13102181 | 0.84 | BCHE (0.79) | BCHEKDM2B | |
| SCHEMBL12155343 | 0.82 | BCHE (0.77) | BCHEKDM2B | |
| SCHEMBL1119617 | 0.80 | GNAI3 (0.51) | SMN1; SMN2 | |
| SCHEMBL3842738 | 0.80 | SMN1; SMN2 (0.68) | BCHEKDM2BSMN1; SMN2 | |
| SCHEMBL10692503 | 0.80 | KDM2B (0.58) | BCHEKDM2BSMN1; SMN2 | |
| SCHEMBL14609068 | 0.79 | KDM2B (0.61) | BCHEKDM2BSMN1; SMN2 | |
| SCHEMBL2600259 | 0.78 | BCHE (0.41) | BCHESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5919799-A | OVERCOMING RESISTANCE TO AN ANTI-NEOPLASTIC AGENT OR AN ENHANCER FOR THE EFFECT OF AN ANTI-NEOPLASTIC AGENT COMPRISING SAID ENHANCER FOR THE EFFECT OF AN ANTI-NEOPLASTIC AGENT | NIKKEN CHEMICALS CO., LTD. (JP) | 1999-07-06 | — | — | US | disclosed |
| EP-0816366-A1 | IMIDAZOTHIAZOLE COMPOUNDS | Nikken Chemicals Company, Limited (JP) | 1998-01-07 | — | — | EP | disclosed |